Richard Kaplan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7930566/publications.pdf

Version: 2024-02-01

41	2,217	236612	288905
papers	citations	25 h-index	40 g-index

41	41	41	2933
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, The, 2019, 393, 143-155.	6.3	265
2	Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community. PLoS ONE, 2012, 7, e34156.	1.1	182
3	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virusâ€“1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clinical Infectious Diseases, 2019, 68, 535-544.	2.9	122
4	Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e1-e8.	0.9	115
5	Substitutions Due to Antiretroviral Toxicity or Contraindication in the First 3 years of Antiretroviral Therapy in a Large South African Cohort. Antiviral Therapy, 2007, 12, 753-760.	0.6	115
6	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infectious Diseases, The, 2019, 19, 253-264.	4.6	114
7	The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Tropical Medicine and International Health, 2009, 14, 722-731.	1.0	113
8	Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. Aids, 2009, 23, 335-342.	1.0	112
9	Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy, 2007, 12, 83-8.	0.6	101
10	Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infectious Diseases, 2012, 12, 21.	1.3	96
11	Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. Aids, 2008, 22, 1679-1681.	1.0	92
12	Burden of New and Recurrent Tuberculosis in a Major South African City Stratified by Age and HIV-Status. PLoS ONE, 2011, 6, e25098.	1.1	87
13	Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. Aids, 2017, 31, 953-963.	1.0	72
14	Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antiviral Therapy, 2007, 12, 753-60.	0.6	67
15	Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa. PLoS ONE, 2013, 8, e55824.	1.1	52
16	Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. BMC Infectious Diseases, 2011, 11, 258.	1.3	41
17	Renal impairment in <scp>HIV</scp>â€infected patients initiating tenofovirâ€containing antiretroviral therapy regimens in a <scp>P</scp>rimary <scp>H</scp>ealthcare <scp>S</scp>etting in <scp>S</scp>outh <scp>A</scp>frica. Tropical Medicine and International Health, 2015, 20, 518-526.	1.0	36
18	Time to Initiation of Antiretroviral Therapy Among Patients With HIV-Associated Tuberculosis in Cape Town, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 136-140.	0.9	34

#	Article	IF	Citations
19	Rates of Switching Antiretroviral Drugs in a Primary Care Service in South Africa before and after Introduction of Tenofovir. PLoS ONE, 2013, 8, e63596.	1.1	34
20	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV,the, 2017, 4, e486-e494.	2.1	31
21	The impact of HIV status and antiretroviral treatment on TB treatment outcomes of new tuberculosis patients attending co-located TB and ART services in South Africa: a retrospective cohort study. BMC Infectious Diseases, 2015, 15, 536.	1.3	29
22	HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PLoS ONE, 2019, 14, e0210937.	1.1	28
23	Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. South African Medical Journal, 2010, 100, 827.	0.2	27
24	The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. Bulletin of the World Health Organization, 2017, 95, 554-563.	1.5	27
25	Outcomes of a nurseâ€managed service for stable <scp>HIV</scp>â€positive patients in a large <scp>S</scp>outh <scp>A</scp>frican public sector antiretroviral therapy programme. Tropical Medicine and International Health, 2014, 19, 1029-1039.	1.0	26
26	Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial. Antiviral Therapy, 2017, 22, 215-223.	0.6	26
27	Increasing Transfers-Out from an Antiretroviral Treatment Service in South Africa: Patient Characteristics and Rates of Virological Non-Suppression. PLoS ONE, 2013, 8, e57907.	1.1	24
28	HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infectious Diseases, 2018, 18, 356.	1.3	22
29	Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-NaÃ¯ve HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, , 1.	0.9	19
30	Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. BMC Infectious Diseases, 2010, 10, 329.	1.3	17
31	Impact of ART on TB Case Fatality Stratified by CD4 Count for HIV-Positive TB Patients in Cape Town, South Africa (2009â€“2011). Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 487-494.	0.9	17
32	Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study. PLoS Medicine, 2017, 14, e1002434.	3.9	16
33	Virological Breakthrough: A Risk Factor for Loss to Followup in a Large Community-Based Cohort on Antiretroviral Therapy. AIDS Research and Treatment, 2011, 2011, 1-6.	0.3	15
34	Promoting Retention in Care: An Effective Model in an Antiretroviral Treatment Service in South Africa. Clinical Infectious Diseases, 2007, 45, 803-803.	2.9	13
35	Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services. South African Medical Journal, 2012, 102, 936.	0.2	11
36	Low prevalence of renal dysfunction in <scp>HIV</scp>â€infected pregnant women: implications for guidelines for the prevention of motherâ€toâ€child transmission of <scp>HIV</scp>. Tropical Medicine and International Health, 2013, 18, 1400-1405.	1.0	9

#	Article	IF	Citations
37	Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study. Antiviral Therapy, 2022, 27, 135965352210774.	0.6	4
38	Resistance to first-line ART and a role for dolutegravir. Lancet HIV,the, 2018, 5, e112-e113.	2.1	3
39	The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE, 2013, 8, e54435.	1.1	2
40	Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective. Aids, 2021, 35, S153-S163.	1.0	1
41	Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy. Lancet Infectious Diseases, The, 2015, 15, 748-749.	4.6	0